AstraZeneca and HUTCHMED Present Positive Phase III Data for Lung Cancer Combination Therapy

AstraZeneca and HUTCHMED presented Phase III data at the ESMO 2026 congress for ORPATHYS (savolitinib) combined with TAGRISSO (osimertinib) in first-line EGFR-mutated non-small cell lung cancer. The results indicated the combination reduced disease progression. The companies jointly developed ORPATHYS, with AstraZeneca responsible for commercialization, highlighting their ongoing oncology collaboration.